A detailed history of Credit Suisse Ag transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Credit Suisse Ag holds 60,202 shares of PRTA stock, worth $1.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,202
Previous 59,304 1.51%
Holding current value
$1.21 Million
Previous $2.16 Million 30.81%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$24.75 - $40.66 $22,225 - $36,512
898 Added 1.51%
60,202 $1.49 Million
Q4 2023

Feb 08, 2024

BUY
$32.31 - $52.32 $244,037 - $395,172
7,553 Added 14.59%
59,304 $2.16 Million
Q3 2023

Nov 13, 2023

SELL
$47.3 - $70.6 $267,055 - $398,607
-5,646 Reduced 9.84%
51,751 $2.5 Million
Q2 2023

Aug 11, 2023

BUY
$48.26 - $78.59 $756,813 - $1.23 Million
15,682 Added 37.59%
57,397 $3.92 Million
Q1 2023

May 10, 2023

BUY
$46.97 - $58.27 $132,831 - $164,787
2,828 Added 7.27%
41,715 $2.02 Million
Q4 2022

Feb 13, 2023

BUY
$52.05 - $65.0 $396,048 - $494,585
7,609 Added 24.33%
38,887 $2.34 Million
Q3 2022

Nov 10, 2022

BUY
$25.16 - $60.63 $89,418 - $215,479
3,554 Added 12.82%
31,278 $1.9 Million
Q2 2022

Aug 12, 2022

BUY
$22.73 - $39.98 $8,387 - $14,752
369 Added 1.35%
27,724 $753,000
Q1 2022

May 16, 2022

BUY
$30.27 - $49.22 $114,511 - $186,199
3,783 Added 16.05%
27,355 $1 Million
Q4 2021

Feb 14, 2022

SELL
$42.11 - $73.26 $69,902 - $121,611
-1,660 Reduced 6.58%
23,572 $1.17 Million
Q3 2021

Nov 12, 2021

BUY
$48.2 - $78.89 $135,104 - $221,128
2,803 Added 12.5%
25,232 $1.8 Million
Q2 2021

Aug 16, 2021

BUY
$21.63 - $57.65 $64,327 - $171,451
2,974 Added 15.29%
22,429 $1.15 Million
Q1 2021

May 14, 2021

SELL
$11.0 - $28.24 $180,708 - $463,926
-16,428 Reduced 45.78%
19,455 $488,000
Q4 2020

Feb 12, 2021

SELL
$10.12 - $13.94 $97,789 - $134,702
-9,663 Reduced 21.22%
35,883 $430,000
Q3 2020

Nov 13, 2020

SELL
$9.93 - $13.47 $74,246 - $100,715
-7,477 Reduced 14.1%
45,546 $455,000
Q2 2020

Aug 12, 2020

BUY
$9.56 - $12.51 $251,925 - $329,663
26,352 Added 98.8%
53,023 $555,000
Q1 2020

May 13, 2020

SELL
$7.54 - $15.77 $5,715 - $11,953
-758 Reduced 2.76%
26,671 $285,000
Q4 2019

Feb 12, 2020

SELL
$7.48 - $17.01 $11,466 - $26,076
-1,533 Reduced 5.29%
27,429 $434,000
Q3 2019

Nov 12, 2019

BUY
$6.89 - $10.45 $22,537 - $34,181
3,271 Added 12.73%
28,962 $227,000
Q2 2019

Aug 14, 2019

SELL
$8.85 - $12.49 $6,318 - $8,917
-714 Reduced 2.7%
25,691 $271,000
Q1 2019

May 14, 2019

SELL
$10.32 - $14.49 $90,176 - $126,613
-8,738 Reduced 24.86%
26,405 $321,000
Q4 2018

Feb 13, 2019

BUY
$8.73 - $13.74 $42,357 - $66,666
4,852 Added 16.02%
35,143 $362,000
Q3 2018

Nov 13, 2018

SELL
$12.7 - $15.79 $133,184 - $165,589
-10,487 Reduced 25.72%
30,291 $396,000
Q2 2018

Aug 14, 2018

SELL
$10.99 - $44.21 $117,318 - $471,941
-10,675 Reduced 20.75%
40,778 $595,000
Q1 2018

May 15, 2018

BUY
$27.95 - $45.04 $66,157 - $106,609
2,367 Added 4.82%
51,453 $1.89 Million
Q4 2017

Feb 14, 2018

SELL
$35.44 - $63.76 $3.35 Million - $6.03 Million
-94,526 Reduced 65.82%
49,086 $1.84 Million
Q3 2017

Nov 14, 2017

BUY
$53.83 - $67.75 $1.01 Million - $1.27 Million
18,703 Added 14.97%
143,612 $9.3 Million
Q2 2017

Aug 14, 2017

BUY
N/A
124,909
124,909 $6.76 Million

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $942M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.